restorex_logo-h-200 is the world's first polymer-based technology platform designed to enable heart valve restoration - through ETR

ETR

ETR enables the patient’s own body to naturally restore a heart valve that is defective or no longer works. With ETR, the patient's natural healing system develops tissue that pervades Xeltis’ heart valve, forming a new, natural and fully functional valve within it.

As ETR occurs, Xeltis’ implants are gradually absorbed by the body. ETR is enabled by the porous structure of Xeltis’ heart valves, which are made of bioabsorbable polymers, based on Nobel-prize awarded science.

ETR in Action

Step 1

Xeltis devices work as normal heart valves or blood vessels once implanted.

Step 1
Step 2

New tissue forms around and inside the device to develop a new, healthy, functioning heart valve.

Step 2
Step 3

Xeltis devices are designed to absorb over time, leaving patients with a new, healthy, functioning heart valve.

Step 3

restorex_logo-h-200 

RestoreX is the world's first polymer-based technology designed to enable natural heart valve restoration. Xeltis technology applies principles of Nobel Prize awarded science of supramolecular chemistry and properties of bioabsorbable polymers to cardiovascular restoration.

No in vitro tissue engineering

No stem cells

No biological agents

No animal tissue

Electrospinning
supramolecular polymers

Using electric force to draw supramolecular polymer solutions into threads that measure a fraction of the diameter of a hair.

20+ international
patent families portfolio
protecting Xeltis’ innovative supramolecular polymer platform and its electrospinning methodology for device manufacturing.

100,000s+ patients
with cardiovascular conditions requiring heart valve replacements potentially addressed with RestoreX technology.

Product Pipeline

restorex_logo-h-200 Technology Outstanding 2-year clinical data at EACTS
In Vitro
Pre-Clinical
Clinical
Pulmonary Heart Valve First commercial product
In Vitro
Pre-Clinical
Clinical
Aortic Heart Valve Extending pipeline to high pressure circuit
In Vitro
Pre-Clinical
Clinical
Additional Applications Further pipeline expansion underway
In Vitro
Pre-Clinical
Clinical
In Vitro
Pre-Clinical
Clinical

Published Data

2017
EuroPCR 2017 annual meeting:
6-month preclinical data on aortic heart valve View PDF
2016
30th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting:
Xeltis 2-year feasibility clinical trial data of a novel bioabsorbable vascular graft in modified Fontan procedure - mid-term results View PDF
2016
30th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting:
Xeltis 1-year in vivo data of a novel bioabsorbable pulmonary heart valved conduit
2016
96th American Association for Thoracic Surgery (AATS) annual meeting: Xeltis 1-year feasibility clinical trial data showed significant improvement in patients’ general conditions. View PDF
2016
3rd Heart Valve Society (HVS) annual meeting: Xeltis 1-year feasibility clinical trial data show significant improvement in patients’s general conditions. View PDF
2016
10th World Biomaterials Congress (WBC) annual meeting: Preclinical data on ETR validated potential of Xeltis technology to “guide the restoration of a patient’s natural tissue into a functional living vascular replacement.” View PDF

Nobel
Prize-Awarded Science

Jean-Marie Lehn, Nobel Laureate Awarded 1987 Nobel Prize in Chemistry for pioneering supramolecular chemistry, the science at the basis of Xeltis’ technology.
“Supramolecular chemistry enables Xeltis technology by providing unique biochemical and biomechanical properties, delivering solutions to issues faced by traditional materials over the course of decades.” Professor Lehn is a Scientific Advisor to Xeltis.
RestoreX technology platform comprises investigational devices that are not available for sale.